期刊文献+

PcDNA3.1(-)-edPSMA载体的构建及其稳转鉴定 被引量:1

Construction of PcDNA 3.1 ( - ) -edPSMA vector and identification of its expression in RM-1 cell line after stable transfection
原文传递
导出
摘要 目的构建人前列腺特异性膜抗原胞外区(edPSMA)真核表达质粒,并建立稳定表达edPSMA的小鼠前列腺癌(RM-1-edPSMA)的细胞株。方法构建PcDNA3.1(-).edPSMA真核表达载体并测序,脂质体转染法分别将PcDNA3.1(-)-edPSMA质粒和PcDNA3.1(-)空载质粒转染至RM-1细胞,G418筛选后获得了稳定生长的阳性克隆细胞株,逆转录-聚合酶链反应(RT—PCR)、Westernblot检测edPSMA蛋白的表达。结果质粒经酶切测序,结果与GeneBank序列进行Blast比对分析,同源性为99.7%,RT—PCR和Westernblot均证明转染了PcDNA3.1(-)-edPS—MA质粒的RM-1细胞表达edPSMA。结论成功构建了PcDNA3.1(-)-edPSMA质粒,并建立了稳定表达edPSMA的细胞株。 Objective To construct the eukaryotic expression plasmid about extraeellular domain of PSMA (edPSMA) and establish an edPSMA-expressing RM-1-edPSMA cells to provide materials for the research of the new vaccine of dendritic cells and the exploration of the immune mechanism. Methods A eukaryotic expression vector pcDNA 3.1 ( -)- edPSMA was constructed and sequenced. The pcDNA 3.1 ( - )-edPSMA and pcDNA3.1 ( - ) plasmids were transfected into RM-1 cell lines using Lipofectamine^TM 2000. These transfected cells were cultured by G418 (200 mg/L). The expression of edPSMA in the survival cells was detected by RT-PCR and Western blot. Results Plasmid was digested, and the amplified fragments had 99.7% homology with the human PSMA published in the Gene bank. The results of RT- PCR and Western blot demonstrated that the RM-1 cells expressing edPSMA had been obtained. Conclusion The PcDNA 3.1 ( - )-edPSMA plasmid and the RM-1 cells stablely expressing edPSMA,were successfully constructed, which provides the basis for the research and application of the new vaccine of dendritic cells.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2009年第5期627-629,共3页 Chinese Journal of Experimental Surgery
基金 国家自然科学基金资助项目:30672107
关键词 前列腺特异性抗原 载体 转染 基因表达 PSMA Vector Transfection Gene expression
  • 相关文献

参考文献14

  • 1Elsasser-Beile U, Buhler P, Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Current Drug Targets ,2009,10 : 118-125.
  • 2刘定益,夏维木.前列腺癌的基因治疗展望[J].中华实验外科杂志,2003,20(2):103-104. 被引量:6
  • 3Hernandez I, Maddison LA, Wei Y, et al. Prostate-specific expression of p53 (R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival. Mol Cancer Res, 2003,1 : 1036-1047.
  • 4Aden PM, Aden PM, Ono T, et al. Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer. Cancer Sci, 2004,95:367-370.
  • 5Nakanishi H, Mazda O, Satoh E, et al. Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo. Gene Ther,2003,10:434-442.
  • 6Eder IE,Haag P,Bartsch G,et al. Gene therapy strategies in prostate cancer. Curr Gene Ther,2005,5 : 1-10.
  • 7Trudel S, Trachtenberg J, Toi A, et al. A phase Ⅰ trial of adenovectormediated delivery of inter-leukin-2 ( AdlL-2 ) in high-riskl localized prostate cancer. Cancer Gene Ther,2003,10:755-763.
  • 8Satoh T,Irie A,Egawa S,et al. In situ gene therapy for prostate canc- er. Curt Gene Ther.2005.5 : 111-119.
  • 9Macrae E J, Giannoudis A, Ryan R. Gene therapy for prostate cancer: Current strategies and new cell-based approaches. Prostate,2006,66: 470-494.
  • 10Arlen PM, Gulley JL. Therapeutic vaccines for prostate cancer: a review of clinical data. Curr Opin Investig Drugs ,2005,6:592-596.

二级参考文献2

  • 1Denis L.Prostate cancer:Primary hormonal treatment.Cancer,1993,71:1050-1057.
  • 2Liljia H.Significance of difference molecular forms of serum PSA.Urol,1993,20:618-623.

共引文献14

同被引文献9

  • 1Jemal A, Siegel R, Ward E, et al. Cancer Statistics,2008. CA Cancer J Clin,2008 ,58 :71-96.
  • 2Eder IE, Haag P, Bartsch G, et al. Gene therapy strategies in prostate cancer. Curr Gene Ther,2005 ,5 :1-10.
  • 3Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol, 1991,9:271-296.
  • 4Klinman DM, Currie D, Gursel I, et al. Use of CpG oligodeoxynueleotides as immune adjuvants. Immunol Rev,2004,199:201-216.
  • 5Nencioni A, Grunebach F, Schmidt SM, et al. The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol, 2008,65: 191-199.
  • 6Nagzraj S, Pisarev V, Kinarsky L, et ah Dendritic cell-based fulllength survivin vaccine in treatment of experimental tumors. J Immunother,2007,30 : 169-179.
  • 7Waeckerle-Men Y,Uetz-von Allmen E, Fopp M, et al. Dendritic cell- based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother,2006,55 : 1524-1533.
  • 8项红兵,肖建斌,招伟贤,高巨,徐珉.表达前强啡肽基因的Ad5型腺病毒载体的构建及鉴定[J].中华实验外科杂志,2008,25(9):1201-1203. 被引量:6
  • 9匡幼林,刘修恒,祝恒成,翁小东,陈志远,江波涛,陈晖,刘东山,沈昊.人前列腺特异性膜抗原胞外区基因重组腺病毒的构建[J].武汉大学学报(医学版),2010,31(2):255-258. 被引量:1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部